Meeting of the Pain Management Best Practices Inter-Agency Task Force, 40303-40304 [2018-17446]
Download as PDF
<![CDATA[
amozie on DSK3GDR082PROD with NOTICES1
Federal Register / Vol. 83, No. 157 / Tuesday, August 14, 2018 / Notices
Print Format in Direct-to-Consumer
Prescription Drug Advertisements on
Risk Knowledge and Preference.’’ Drug
Information Journal, vol. 36(3), pp. 693–
705, 2002.
7. Brief Summary and Adequate Directions
for Use: Disclosing Risk Information in
Consumer-Directed Print Advertisements
and Promotional Labeling for
Prescription Drugs. Revised Draft
Guidance. Available at https://
www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatory
Information/Guidances/UCM069984.pdf.
8. ‘‘Content of Risk Information in the Major
Statement in Prescription Drug Direct-toConsumer Broadcast Advertisements;
Establishment of a Public Docket;
Request for Information and Comments.’’
August 21, 2017, 82 FR 39598.
9. Betts, Kevin R., et al., ‘‘Serious and
Actionable Risks, Plus Disclosure:
Investigating an Alternative Approach
for Presenting Risk Information in
Prescription Drug Television
Advertisements.’’ Research in Social and
Administrative Pharmacy, 2017.
10. Bhutada, N.S., B.L. Rollins, and M. Perri
III, ‘‘Impact of Animated SpokesCharacters in Print Direct-to-Consumer
Prescription Drug Advertising: An
Elaboration Likelihood Model
Approach.’’ Health Communication, vol.
32, pp. 391–400, 2017.
11. Zaichkowsky, J.L., ‘‘The Personal
Involvement inventory: Reduction,
Revision, and Application to
Advertising.’’ Journal of Advertising, vol.
23, pp. 59–70, 1994.
12. Mackert, M., S.E. Champlin, K.E. Pasch,
and B.D. Weiss, ‘‘Understanding Health
Literacy Measurement Through Eye
Tracking.’’ Journal of Health
Communication, vol. 18, pp. 185–196,
2013.
13. Chiang, K.P. and A. Jackson, ‘‘The Impact
of Health Literacy on Involvement and
Attitude Toward Pharmaceutical Print
Ads.’’ International Journal of
Healthcare Management, vol. 9(1), pp.
47–57, 2016.
14. An, S. and N. Muturi, ‘‘Subjective Health
Literacy and Older Adults’ Assessment
of Direct-to Consumer Prescription Drug
Ads.’’ Journal of Health Communication,
vol. 16(3), pp. 242–255, 2011.
15. Ball, J.G., D. Manika, and P. Stout,
‘‘Consumers Young and Old: Segmenting
the Target Markets for Direct-toConsumer Prescription Drug
Advertising.’’ Health Marketing
Quarterly, vol. 28(4), pp. 337–353, 2011.
16. Christensen, T.P., F.J. Ascione, and R.P.
Bagozzi, ‘‘Understanding How Elderly
Patients Process Drug Information: A
Test of a Theory of Information
Processing.’’ Pharmaceutical Research,
vol. 14, pp. 1589–1596, 1997.
17. Mehta, A. and S.C. Purvis, ‘‘Consumer
Response to Print Prescription Drug
Advertising.’’ Journal of Advertising
Research, vol. 43(2), pp. 194–206, 2003.
18. Paulhus, D.L. and S. Vazire, ‘‘The SelfReport Method.’’ Handbook of Research
Methods in Personality Psychology, vol.
1, pp. 224–239, 2007.
VerDate Sep<11>2014
19:13 Aug 13, 2018
Jkt 244001
Dated: August 8, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–17360 Filed 8–13–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
The Biomedical Advanced Research
and Development Authority (BARDA)
Assistant Secretary for
Preparedness and Response, HHS.
ACTION: Notice.
AGENCY:
The Biomedical Advanced
Research and Development Authority
(BARDA), Office of the Assistant
Secretary for Preparedness and
Response (ASPR), in the Department of
Health and Human Services intends to
provide a Single Source Cooperative
Agreement to Janssen Research &
Development, LLC. The Cooperative
Agreement will support QuickFire
Challenges to spur innovation in
respiratory protection. The total
proposed cost of the Single Source
Cooperative Agreement is not to exceed
$100,000 for a total of 12 months.
DATES:
Project Period: The period of
performance is from July 30, 2018 to
June 30, 2019.
Award amount: Estimate $100,000.
FOR FURTHER INFORMATION CONTACT:
Sherrette.Funn@hhs.gov, 202–795–7714,
Julie.Schafer@hhs.gov, 202–205–1435.
SUPPLEMENTARY INFORMATION: The
Biomedical Advanced Research and
Development Authority (BARDA) is the
program office for this Cooperative
Agreement:
Single Source Justification: Janssen
Research & Development, LLC creates
global challenges to spur innovation in
health care in partnership with JLABS,
a global network of open innovation
ecosystems designed to support
innovators and entrepreneurs in
creating and accelerating innovative
health care solutions.
Janssen Research & Development, LLC
and BARDA will collaborate on a global
challenge for reimagined, transformative
respiratory protection. Traditional
respiratory protective devices used to
protect against inhalation of harmful
infectious agents were designed for use
in occupational settings, to guard
against inhalation of dangerous
particulates. Disposable versions, such
as N95 respirators, are only available for
adults, must be fit-tested to ensure
proper functioning, and can be
uncomfortable to wear. In an outbreak of
a novel or newly emerging respiratory
SUMMARY:
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
40303
disease, respiratory protection may be
the only countermeasure available to
protect health care workers and the
general public.
Janssen Research & Development, LLC
will partner with JLABS, which exists to
foster innovation in health care
products and executes QuickFire
Challenges for health care innovation.
There is no direct equivalent of the
QuickFire Challenge services for
innovation specific to health care as is
provided by JLABS. Its unique service
will directly benefit BARDA’s mission
to make available medical
countermeasures to address health
security threats. Supporting innovation
is an authority provided to BARDA
under the Public Health Service Act and
partnering with a company providing a
diverse array of products and leveraging
its expertise and infrastructure has the
potential to provide solutions to the
challenges in developing new
respiratory devices.
Reimagined, innovative respiratory
protection would contribute directly to
ASPR’s mission to save lives and protect
Americans against 21st Century health
security threats. Respiratory protection
is often the first line of defense, and a
radically improved approach to protect
both health care workers and the general
public, including children, would truly
improve our ability to respond to public
health emergencies. By generating
interest and focusing innovation efforts
on reimagining respiratory protection,
BARDA’s goal for the QuickFire
Challenge is for the resulting innovative
approaches to be eligible for continued
testing and development and eventual
regulatory approval, so that these
revolutionary products can be widely
available and used.
Please submit an inquiry via the
ASPR–BARDA Program Contact: Dr.
Julie Schafer, Julie.Schafer@hhs.gov,
202–205–1435.
Robert P. Kadlec,
Assistant Secretary for Preparedness and
Response.
[FR Doc. 2018–17381 Filed 8–13–18; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Pain Management Best
Practices Inter-Agency Task Force
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
E:\FR\FM\14AUN1.SGM
14AUN1
40304
Federal Register / Vol. 83, No. 157 / Tuesday, August 14, 2018 / Notices
As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that a meeting is scheduled to be held
for the Pain Management Best Practices
Inter-Agency Task Force (Task Force).
The meeting will be open to the public;
public comment sessions will be held
during the meeting.
DATES: The Task Force meeting will be
held on Tuesday, September 25, 2018,
from 8:30 a.m. to 4:30 p.m. Eastern Time
(ET) and Wednesday, September 26,
2018, from 9:00 a.m. to 12:00 p.m. ET.
The agenda will be posted on the Task
Force website at https://www.hhs.gov/
ash/advisory-committees/pain/
index.html.
SUMMARY:
U.S. Department of Health
and Human Services, Hubert H.
Humphrey Building, Great Hall, 200
Independence Avenue SW, Washington,
DC 20201.
FOR FURTHER INFORMATION CONTACT:
Alicia Richmond Scott, Designated
Federal Officer, Pain Management Best
Practices Inter-Agency Task Force, U.S.
Department of Health and Human
Services, Office of the Assistant
Secretary for Health, 200 Independence
Avenue SW, Room 736E, Washington,
DC 20201. Phone: 240–453–2816. Email:
paintaskforce@hhs.gov.
SUPPLEMENTARY INFORMATION: Section
101 of the Comprehensive Addiction
and Recovery Act of 2016 (CARA)
requires the Secretary of Health and
Human Services, in cooperation with
the Secretaries of Defense and Veterans
Affairs, to convene the Task Force no
later than two years after the date of the
enactment of CARA and develop a
report to Congress with updates on best
practices and recommendations on
addressing gaps or inconsistencies for
pain management, including chronic
and acute pain. The Task Force is
governed by the provisions of the
Federal Advisory Committee Act
(FACA), Public Law 92–463, as
amended (5 U.S.C. App), which sets
forth standards for the formation and
use of advisory committees.
The Task Force will review clinical
guidelines and identify gaps and/or
inconsistencies for best practices for
pain management, including chronic
and acute pain, developed or adopted
by federal agencies; propose updates to
best practices and recommendations for
identified gaps or inconsistencies;
provide a 90 day the public comment
period on any proposed updates and
recommendations; and develop a
strategy for disseminating such
proposed updates and recommendations
amozie on DSK3GDR082PROD with NOTICES1
ADDRESSES:
VerDate Sep<11>2014
19:13 Aug 13, 2018
Jkt 244001
to relevant federal agencies and the
general public.
The Task Force will convene its
second public meeting, on September 25
and 26, 2018, to discuss updates to
existing best practices and
recommendations based on gaps and
inconsistencies for pain management,
including chronic and acute pain. The
Task Force will receive presentations
from three Task Force subcommittees
established at the inaugural Task Force
meeting. The Task Force subcommittees
will discuss recommendations for
updates to best practices and
recommendations for chronic and acute
pain management and prescribing pain
medication based on the components
outlined in Section 101 of the CARA
statute. The Task Force will deliberate
and vote on the draft Task Force
recommendations. Information about
the final meeting agenda will be posted
prior to the meeting on the Task Force
website: https://www.hhs.gov/ash/
advisorycommittees/pain/.
Members of the public are invited to
participate in person or by webcast. To
join the meeting, individuals must preregister at the Task Force website at
https://www.hhs.gov/ash/advisorycommittees/pain/. Seating
will be provided first to those who have
pre-registered. Anyone who has not preregistered will be accommodated on a
first come, first served basis if
additional seats are available 10 minutes
before the meeting starts. Individuals
who need special assistance, such as
sign language interpretation or other
reasonable accommodations, should
indicate the special accommodation
when registering online or by notifying
the Office of the Assistant Secretary for
Health via email at paintaskforce@
hhs.gov by September 21, 2018. The
subject line of the email should read,
‘‘Task Force Meeting
Accommodations.’’ Non-U.S. citizens
who plan to attend in person are
required to provide additional
information and must notify the Task
Force staff via email at paintaskforce@
hhs.gov 10 business days before the
meeting, September 11, 2018. For those
unable to attend in person, a live
webcast will be available. More
information on registration and
accessing the webcast can be found at
https://www.hhs.gov/ash/advisorycommittees/pain/.
Members of the public can provide
oral comments at the Task Force
meeting on September 25, 2018, at 9:20
a.m.–9:50 a.m. ET. Please indicate your
willingness to provide oral comments
on the registration form which can be
found at https://www.hhs.gov/ash/
advisory-committees/pain/.
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
Individuals who pre-register will be
given priority to provide oral public
comment within the order they are
received. The public comment period
will not be extended beyond the allotted
time on the agenda. Public comments
made during the meeting will be limited
to three minutes per person to ensure
time is allotted for all those wishing to
speak. Please note that the public
comment period may end before the
time indicated, following the last call
for comments. Individuals who are not
able to provide oral comments are
encouraged to submit their written
comments. Written comments should
not exceed one page in length.
Individuals submitting written
comments should submit their
comments through the Federal
eRulemaking Portal at https://
www.regulations.gov, docket number
HHS–OS–2018–0016.
Dated: August 9, 2018.
Vanila M. Singh,
Chief Medical Officer, Chair, Pain
Management Task Force, Office of the
Assistant Secretary for Health.
[FR Doc. 2018–17446 Filed 8–13–18; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2018–0280]
Collection of Information Under
Review by Office of Management and
Budget; OMB Control Number: 1625–
0045
Coast Guard, DHS.
Thirty-day notice requesting
comments.
AGENCY:
ACTION:
In compliance with the
Paperwork Reduction Act of 1995 the
U.S. Coast Guard is forwarding an
Information Collection Request (ICR),
abstracted below, to the Office of
Management and Budget (OMB), Office
of Information and Regulatory Affairs
(OIRA), requesting an extension of its
approval for the following collection of
information: 1625–0045, Adequacy
Certification for Reception Facilities and
Advance Notice—33 CFR part 158,
without change. Our ICR describes the
information we seek to collect from the
public. Review and comments by OIRA
ensure we only impose paperwork
burdens commensurate with our
performance of duties.
DATES: Comments must reach the Coast
Guard and OIRA on or before September
13, 2018.
SUMMARY:
E:\FR\FM\14AUN1.SGM
14AUN1
]]>Agencies
[Federal Register Volume 83, Number 157 (Tuesday, August 14, 2018)]
[Notices]
[Pages 40303-40304]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-17446]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Pain Management Best Practices Inter-Agency Task
Force
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
[[Page 40304]]
SUMMARY: As stipulated by the Federal Advisory Committee Act, the
Department of Health and Human Services (HHS) is hereby giving notice
that a meeting is scheduled to be held for the Pain Management Best
Practices Inter-Agency Task Force (Task Force). The meeting will be
open to the public; public comment sessions will be held during the
meeting.
DATES: The Task Force meeting will be held on Tuesday, September 25,
2018, from 8:30 a.m. to 4:30 p.m. Eastern Time (ET) and Wednesday,
September 26, 2018, from 9:00 a.m. to 12:00 p.m. ET. The agenda will be
posted on the Task Force website at https://www.hhs.gov/ash/advisory-committees/pain/.
ADDRESSES: U.S. Department of Health and Human Services, Hubert H.
Humphrey Building, Great Hall, 200 Independence Avenue SW, Washington,
DC 20201.
FOR FURTHER INFORMATION CONTACT: Alicia Richmond Scott, Designated
Federal Officer, Pain Management Best Practices Inter-Agency Task
Force, U.S. Department of Health and Human Services, Office of the
Assistant Secretary for Health, 200 Independence Avenue SW, Room 736E,
Washington, DC 20201. Phone: 240-453-2816. Email:
[email protected].
SUPPLEMENTARY INFORMATION: Section 101 of the Comprehensive Addiction
and Recovery Act of 2016 (CARA) requires the Secretary of Health and
Human Services, in cooperation with the Secretaries of Defense and
Veterans Affairs, to convene the Task Force no later than two years
after the date of the enactment of CARA and develop a report to
Congress with updates on best practices and recommendations on
addressing gaps or inconsistencies for pain management, including
chronic and acute pain. The Task Force is governed by the provisions of
the Federal Advisory Committee Act (FACA), Public Law 92-463, as
amended (5 U.S.C. App), which sets forth standards for the formation
and use of advisory committees.
The Task Force will review clinical guidelines and identify gaps
and/or inconsistencies for best practices for pain management,
including chronic and acute pain, developed or adopted by federal
agencies; propose updates to best practices and recommendations for
identified gaps or inconsistencies; provide a 90 day the public comment
period on any proposed updates and recommendations; and develop a
strategy for disseminating such proposed updates and recommendations to
relevant federal agencies and the general public.
The Task Force will convene its second public meeting, on September
25 and 26, 2018, to discuss updates to existing best practices and
recommendations based on gaps and inconsistencies for pain management,
including chronic and acute pain. The Task Force will receive
presentations from three Task Force subcommittees established at the
inaugural Task Force meeting. The Task Force subcommittees will discuss
recommendations for updates to best practices and recommendations for
chronic and acute pain management and prescribing pain medication based
on the components outlined in Section 101 of the CARA statute. The Task
Force will deliberate and vote on the draft Task Force recommendations.
Information about the final meeting agenda will be posted prior to the
meeting on the Task Force website: https://www.hhs.gov/ash/advisorycommittees/pain/.
Members of the public are invited to participate in person or by
webcast. To join the meeting, individuals must pre-register at the Task
Force website at https://www.hhs.gov/ash/advisory-committees/pain/. Seating will be provided first to those who have pre-
registered. Anyone who has not pre-registered will be accommodated on a
first come, first served basis if additional seats are available 10
minutes before the meeting starts. Individuals who need special
assistance, such as sign language interpretation or other reasonable
accommodations, should indicate the special accommodation when
registering online or by notifying the Office of the Assistant
Secretary for Health via email at [email protected] by September
21, 2018. The subject line of the email should read, ``Task Force
Meeting Accommodations.'' Non-U.S. citizens who plan to attend in
person are required to provide additional information and must notify
the Task Force staff via email at [email protected] 10 business
days before the meeting, September 11, 2018. For those unable to attend
in person, a live webcast will be available. More information on
registration and accessing the webcast can be found at https://www.hhs.gov/ash/advisory-committees/pain/.
Members of the public can provide oral comments at the Task Force
meeting on September 25, 2018, at 9:20 a.m.-9:50 a.m. ET. Please
indicate your willingness to provide oral comments on the registration
form which can be found at https://www.hhs.gov/ash/advisory-committees/pain/. Individuals who pre-register will be given priority to
provide oral public comment within the order they are received. The
public comment period will not be extended beyond the allotted time on
the agenda. Public comments made during the meeting will be limited to
three minutes per person to ensure time is allotted for all those
wishing to speak. Please note that the public comment period may end
before the time indicated, following the last call for comments.
Individuals who are not able to provide oral comments are encouraged to
submit their written comments. Written comments should not exceed one
page in length. Individuals submitting written comments should submit
their comments through the Federal eRulemaking Portal at https://www.regulations.gov, docket number HHS-OS-2018-0016.
Dated: August 9, 2018.
Vanila M. Singh,
Chief Medical Officer, Chair, Pain Management Task Force, Office of the
Assistant Secretary for Health.
[FR Doc. 2018-17446 Filed 8-13-18; 8:45 am]
BILLING CODE 4150-28-P
